• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

    2/12/24 9:26:34 AM ET
    $BRTX
    Managed Health Care
    Health Care
    Get the next $BRTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Broadrick Dale

    (Last) (First) (Middle)
    3003 BRICK CHURCH PIKE

    (Street)
    NASHVILLE TN 37207

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioRestorative Therapies, Inc. [ BRTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/08/2024 P 73,959 A $1.25 391,931 I Ssee Footnote(1)
    Common Stock 02/09/2024 P 86,041 A $1.32 477,972 I See Footnote(1)
    Common Stock 447,045 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrant to acquire Common Stock $120 02/19/2019 02/19/2024 Common Stock 250 250 D
    Warrant to acquire Common Stock $120 05/07/2019 05/07/2024 Common Stock 276 276 D
    Warrant to acquire Common Stock $120 10/16/2019 10/16/2024 Common Stock 833 833 D
    Explanation of Responses:
    1. Owned by Fleetco, Inc. of which the reporting person is a 93% shareholder.
    /s/ Dale Broadrick 02/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BRTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRTX

    DatePrice TargetRatingAnalyst
    12/1/2021$37.00Buy
    Roth Capital
    More analyst ratings

    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Silva Francisco bought $10,229 worth of shares (8,308 units at $1.23), increasing direct ownership by 6% to 155,759 units (SEC Form 4)

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    4/10/24 5:16:36 PM ET
    $BRTX
    Managed Health Care
    Health Care

    Broadrick Dale bought $206,023 worth of shares (160,000 units at $1.29) (SEC Form 4)

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    2/12/24 9:26:34 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Broadrick Dale bought $162,255 worth of shares (120,000 units at $1.35), increasing direct ownership by 37% to 447,045 units (SEC Form 4)

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    2/9/24 8:00:31 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    SEC Filings

    View All

    SEC Form D filed by BioRestorative Therapies Inc.

    D - BioRestorative Therapies, Inc. (0001505497) (Filer)

    10/9/25 12:50:56 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    10/8/25 5:10:43 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form 424B5 filed by BioRestorative Therapies Inc.

    424B5 - BioRestorative Therapies, Inc. (0001505497) (Filer)

    10/8/25 4:25:27 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

    MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Lance Alstodt, BioRestorative's CEO, and Francisco Silva, the Company's Vice President of Research and Development, will be participating in a panel titled "Stem Cell Therapy – A Space That is Ready to have its Day," to be moderated by Jason McCarthy, Ph.D., Maxim Group's Senior Managing Director, Head of Biotechnology R

    10/15/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show"

    MELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today is pleased to announce that its CEO, Lance Alstodt, participated in an interview with "The Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show. During the interview, Mr. Alstodt discussed BioRestorative's recent achievements of key clinical and regulatory milestones, as well as highlighted some of the significant commercial opportunities that the Company is pursuing. The interview has or will be aired on cable TV and streaming services,

    10/7/25 9:25:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by BioRestorative Therapies Inc.

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    10/20/25 8:18:15 AM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form 4 filed by BioRestorative Therapies Inc.

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    10/20/25 8:02:27 AM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form 4 filed by Director Rosa David A

    4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)

    2/19/25 4:33:37 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on BioRestorative Therapies with a new price target

    Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00

    12/1/21 10:21:36 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Leadership Updates

    Live Leadership Updates

    View All

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

    MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Mr. Lipkins has an accom

    6/10/25 8:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

    MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi

    1/11/22 6:00:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Financials

    Live finance-specific insights

    View All

    BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

    MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, Chief Executive Officer of BioRestorative. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and see many potential value

    8/12/25 4:05:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

    MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2025 Results Conference Call Details: Date:Tuesday, August 12, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:436077 The call will al

    8/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

    MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, the Company's Chief Executive Officer. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and we see many potential value e

    5/14/25 4:05:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    3/6/24 4:34:22 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    2/15/24 4:43:54 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form SC 13D/A filed by BioRestorative Therapies Inc. (Amendment)

    SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)

    2/15/24 4:40:53 PM ET
    $BRTX
    Managed Health Care
    Health Care